Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With Gastric Cancer

NCT04202601 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT04202601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04202601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With Gastric Cancer
Lead sponsor
Peking University
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 13, 2019
Completion date
December 1, 2022
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric or gastroesophageal junction (gej) adenocarcinoma